Zhou S L, Shen G, Zhong H F
Department of Pharmacy, Children's Hospital, Shanghai Medical University, People's Republic of China.
Clin Pharmacokinet. 1992 Feb;22(2):144-51. doi: 10.2165/00003088-199222020-00005.
In the present study, ribostamycin concentrations in serum were measured by microbiological assay in 20 paediatric patients aged 3 months to 11 years after intramuscular ribostamycin 10, 15 and 20 mg/kg. All pharmacokinetic parameters and statistical analyses were calculated by computer. These results showed that the absorption rate constant (ka), elimination rate constant (ke), time to peak serum concentration (tmax), elimination half-life (t1/2), apparent volume of distribution (Vd/F), total body clearance (CL) and area under the serum concentration-time curve (AUC) were significantly different in infants under 6 months from those in children over 3 years (p less than 0.05), except for the peak serum concentration (Cmax) and lag time from administration to the first appearance of drug in the serum (tlag) [p greater than 0.05]. The absorption of ribostamycin in infants was more rapid than that in children, but elimination was slower (p less than 0.05). The Vd/F and CL in infants were also larger than in children (p less than 0.01). There were significant positive correlations between Cmax, AUC and ribostamycin dosage (p less than 0.01). Pharmacokinetic parameters for infants and children were compared with those observed in adults, and it was found that ribostamycin absorption and elimination were more rapid in the paediatric patients. The Cmax in children and infants after intramuscular ribostamycin 10 mg/kg approached that in adults after an intramuscular dose of ribostamycin 500mg. Using a 1-compartment open pharmacokinetic model, the optimum intramuscular ribostamycin administration interval was estimated as 6.01 and 7.56h for children and infants, respectively, while the value was 8.5h in adults. When the drug was administered in multiple doses of 15 mg/kg intramuscularly every 8h, no accumulation occurred in children. It is suggested that ribostamycin be administered in intramuscular doses of 10 to 15 mg/kg twice daily in infants and 3 times daily in children, respectively.
在本研究中,对20名年龄在3个月至11岁的儿科患者在肌内注射10、15和20mg/kg核糖霉素后,通过微生物测定法测定血清中的核糖霉素浓度。所有药代动力学参数和统计分析均通过计算机计算。结果表明,6个月以下婴儿的吸收速率常数(ka)、消除速率常数(ke)、血清浓度达峰时间(tmax)、消除半衰期(t1/2)、表观分布容积(Vd/F)、总体清除率(CL)和血清浓度-时间曲线下面积(AUC)与3岁以上儿童有显著差异(p<0.05),但血清峰浓度(Cmax)和给药至血清中首次出现药物的延迟时间(tlag)除外[p>0.05]。婴儿体内核糖霉素的吸收比儿童更快,但消除更慢(p<0.05)。婴儿的Vd/F和CL也高于儿童(p<0.01)。Cmax、AUC与核糖霉素剂量之间存在显著正相关(p<0.01)。将婴儿和儿童的药代动力学参数与成人观察到的参数进行比较,发现儿科患者中核糖霉素的吸收和消除更快。肌内注射10mg/kg核糖霉素后,儿童和婴儿的Cmax接近成人肌内注射500mg核糖霉素后的Cmax。采用单室开放药代动力学模型,估计儿童和婴儿肌内注射核糖霉素的最佳给药间隔分别为6.01和7.56小时,而成人为8.5小时。当每8小时肌内注射15mg/kg多剂量药物时,儿童体内无蓄积现象。建议婴儿肌内注射核糖霉素的剂量为10至15mg/kg,每日两次,儿童每日三次。